Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic γ9δ2 T Cells for Recurrent Hematologic Tumors
NCT05755854Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic gamma9delta2 T cells in hematologic malignancy, sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Incidence of Adverse Events at 12 months and Incidence of Dose-Limiting Toxicities at 14 days. Started May 2023; status: recruiting.
02
Drugs
allogeneic gamma9delta2 T cells
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT05755854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755854.